SI-BONE Q2 revenue $25.6M (+15% YoY); net loss $18.5M ($0.54/share)

SI-BONE, Inc.

2022-Q2 EPS reported -$1.06 revenue$48,024,000

Record worldwide revenue $25.6M, up 15% YoY; U.S. revenue $23.8M, up 18% YoY.
Gross margin 86% vs 89% YoY; operating loss $17.9M vs $13.0M.
Net loss $18.5M ($0.54 per diluted share) vs $14.0M ($0.42) in Q2 2021.
Cash $114.4M; long-term borrowings $35.1M; FY2022 revenue guidance reaffirmed at $106-108M.
FDA clearances for iFuse-TORQ pelvic fractures and iFuse Bedrock Granite; CMS NTAP up to $9,828.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.